Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol

• Published in: Pilot and feasibility studies Vol. 8; no. 1; pp. 1 - 180
• Main Authors: Hutchings, Hayley A, Lanyon, Kirsty, Lister, Steven, Alikhan, Raza, Halcox, Julian, Holland, Gail, Hughes, Arfon, Jenkins, Rhys, Laing, Hamish, Lobban, Trudie, Owen, Diane, Pollock, Kevin G, Todd, Ceri, Wareham, Kathie
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.08.2022; BioMed Central; BMC
• Subjects: Analysis; Anticoagulants; Atrial fibrillation; Bleeding; Cardiac arrhythmia; Consent; Coronaviruses; COVID-19; Disease; Feasibility; Feasibility studies; Health aspects; Heart; Heart beat; Heart rate; Hospitals; Measuring instruments; Medical research; Medicine, Experimental; Mortality; Patient-reported outcome measures; Patients; Primary care; Protocol; Public health; QoL; Quality of life; Stroke; Study Protocol; Thromboembolism; Virtual communities; United Kingdom > UK
• ISSN: 2055-5784; 2055-5784
• DOI: 10.1186/s40814-022-01135-8

Background Oral anticoagulation therapies (OATs) are often prescribed in conjunction with medications to restore normal heart rate rhythm which can limit the risk of an atrial fibrillation (AF) related stroke and systemic thromboembolism. However, they are associated with the serious side effect of bleeding. Both clinically relevant nonmajor bleeding (CRNMB) and major bleeding while anticoagulated are believed to have a significant impact on patient quality of life (QoL). There is currently limited research into the effect bleeding has on QoL. The aim of this study is to evaluate the feasibility of identifying and recruiting patients diagnosed with AF, who are taking OATs and have recently experienced a bleed and collecting information on their QoL. Methods We will recruit a minimum of 50 patients to this cross-sectional, observational study. We will recruit from general practices, secondary care, and through an online AF forum. We will ask participants to complete three validated patient-reported outcome measures (PROMs), EQ5D, AFEQT, and PACT-Q, approximately 4 weeks following a bleed and again 3 months later. We will randomly select a subset of 10 participants (of those who agree to be interviewed) to undergo a structured interview with a member of the research team to explore the impact of bleeding on their QoL and to gain feedback on the three PROMs used. We will undertake a descriptive analysis of the PROMs and demographic data. We will analyse the qualitative interviews thematically to identify key themes. Discussion We aim to establish if it is possible to recruit patients and use PROMs to collect information regarding how patient QoL is affected when they experience either a clinically relevant non-major bleed (CRNMB) or major bleed while taking OATs for the management of AF. We will also explore the appropriateness, or otherwise, of the three identified PROMs for assessing quality of life following a bleed. PROMs Three PROMs were selected following a literature review of similar QoL studies and using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist for comparison. A review of the current literature produced no suitable validated PROM to record QoL experiences in patients who have been diagnosed with AF and have experienced a bleed while anticoagulated. As such, the EQ5D, AFEQT, and PACT-Q (part 2) were deemed most appropriate for use in this feasibility study. Trial registration The trial has been adopted onto the NIHR Portfolio (ID no. 47771) and registered with www.ClinicalTrials.gov (no. NCT04921176) retrospectively registered in June 2021. Keywords: Atrial fibrillation, Bleeding, QoL, Patient-reported outcome measures, Feasibility, Protocol, Anticoagulation